Skip to main content

Purple Innovation, Inc.

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

PRPL$1.80-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(unaudited – in thousands)

Total
Class A Common Stock · Class B Common Stock · Additional Paid-in · Accumulated · Stockholders’ Equity · Noncontrolling · Total Equity
SharesPar ValueSharesPar ValueCapitalDeficit(Deficit)Interest(Deficit)
Balance – December 31, 2024107,545$11165$—$594,053$(573,866)$20,198$11$20,209
Net loss—————(19,137)(19,137)(29)(19,166)
Stock-based compensation————368—368—368
Issuance of stock under equity compensation plans410———(81)—(81)—(81)
Impact of transactions affecting NCI————(8)—(8)8—
Balance – March 31, 2025107,955$11165$—$594,332$(593,003)$1,340$(10)$1,330
Net loss—————(17,345)(17,345)(26)(17,371)
Stock-based compensation————477—477—477
Issuance of stock under equity compensation plans289———(100)—(100)—(100)
Accrued Distribution True-up————85—85—85
Impact of transactions affecting NCI————(96)—(96)96—
Balance – June 30, 2025108,244$11165$—$594,698$(610,348)$(15,639)$60$(15,579)
Class A · Class B · Additional · Total
Common Stock · Common Stock · Paid-in · Accumulated · Stockholders’ · Noncontrolling · Total
SharesPar ValueSharesPar ValueCapitalDeficitEquityInterestEquity
Balance – December 31, 2023105,507$11205$—$591,380$(475,969)$115,422$185$115,607
Net loss—————(50,217)(50,217)(51)(50,268)
Stock-based compensation————492—492—492
Issuance of stock for Intellibed acquisition1,500————————
Issuance of stock under equity compensation plans473———(115)—(115)—(115)
Impact of transactions affecting NCI————(33)—(33)33—
Balance – March 31, 2024107,480$11205$—$591,724$(526,186)$65,549$167$65,716
Net income (loss)—————2727(36)(9)
Stock-based compensation————825—825—825
Issuance of common stock under equity compensation plans23————————
Impact of transactions affecting NCI————(8)—(8)8—
Balance – June 30, 2024107,503$11205$—$592,541$(526,159)$66,393$139$66,532
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.